热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 抗体 Biosimilar抗体

所有图片（1/2）

Anti-Human SLAMF7 Monoclonal Antibody (Elotuzumab)

SLAM family member 7,CD2 subset 1,CD2-like receptor-activating cytotoxic cells (CRACC),Membrane protein FOAP-12,Novel Ly9,Protein 19A,CD319,CS1

价格 询价 请咨询客服
货号 S0E0045
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 宿主来源

    Human

  • 抗原名称

    SLAMF7

  • 分子别名

    SLAM family member 7; CD2 subset 1; CD2-like receptor-activating cytotoxic cells (CRACC); Membrane protein FOAP-12; Novel Ly9; Protein 19A; CD319; CS1

  • 细胞定位

    Membrane

  • Accession

    Q9NQ25

  • 克隆号

    S-4608

  • 抗体类型

    Recombinant mAb

  • 抗体同种型

    IgG1

  • 反应种属 ?

    Hu

  • 纯化方式

    Protein A

  • 浓度

    5 mg/ml

  • 内毒素含量

    <1EU/mg

  • 标记

    Unconjugated

  • 性状

    Liquid

  • 缓冲体系

    PBS pH7.4, containing no preservative

  • 储存条件

    2 to 8 °C for 2 weeks under sterile conditions;
    -20 °C for 3 months under sterile conditions;
    -80 °C for 24 months under sterile conditions.
    Please avoid repeated freeze-thaw cycles.

  • 应用

    Blocking of SLAMF7 signaling Functional assays

背景介绍

  • SLAMF7, also termed CD319 or CS1, is a 66 kDa self-ligating type-I trans-membrane glycoprotein of the CD2/SLAM immunoglobulin superfamily that is constitutively expressed on NK cells, activated B cells, monocytes and, at very high levels, on multiple-myeloma cells; its cytoplasmic tail contains ITSM sequences that, depending on the simultaneous presence or absence of the adaptor proteins EAT-2 and SAP, can switch between activating (via PI3K-PLCγ-ERK) and inhibitory signaling, thereby modulating NK-cell cytotoxicity, B-cell proliferation, macrophage cytokine release and antibody-dependent myeloma killing, making it both an immunomodulatory receptor and the therapeutic target of the FDA-approved monoclonal antibody elotuzumab.

  • 免疫印迹

    • WB result of Anti-Human SLAMF7 Monoclonal Antibody (Elotuzumab)
      Primary antibody: Anti-Human SLAMF7 Monoclonal Antibody (Elotuzumab) at 1/1000 dilution
      Lane 1: SLAMF7/CRACC/CD319 His Tag Protein, Mouse 1 µg
      Lane 2: SLAMF7/CRACC/CD319 His Tag Protein, Human 1 µg
      Secondary antibody: Goat Anti- human IgG, (H+L), HRP conjugated at 1/10000 dilution
      Predicted MW: 37 kDa
      Observed MW: 35-40 kDa

  • ELISA

    • Immobilized SLAMF7/CRACC/CD319 His Tag Protein, Human(UA010412) can bind Elotuzumab. The EC50 for this effect is 7.221 ng/mL.

评论(0)